Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Turoctocog alfa for ITI in Haemophilia A with inhibitors
NCT03588741Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Countries
- 7
01
Overview
Phase 3, open-label trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of Adverse Events at 12 months. Started Jun 2018; status: terminated.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03588741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588741.